Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0035412 (rhabdomyosarcoma)
6,156 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Nine cases of untreatable tumour in which radical surgery was employed palliatively are presented. Three hemipelvectomies for recurrent rhabdomyosarcoma were performed. In one case, death occurred postoperatively, probably as a result of pulmonary embolism. One patient survived for 8 months, while the other is still alive after three years. Of two cases in which interscapulothoracic disarticulation was performed, survivals of 9 and 5 months were observed in subjects with fibrosarcoma in a mastectomy site and recurrent sarcoma of the humerus with ling metastases. Survival to 7 months was obtained in a case of sarcoma of the maxilla, while three patients with squama cell cancer of the mouth floor, chondrosarcoma of the mandible and botryoid sarcoma of the tonsillar fossa are still living after periods of 10 months to 2 yr. Though devoid of schematic indications, palliative demolition surgery can be considered in borderline cases where the operative risk is not high. Irrespective of "quantity", the "quality" of life remaining to the patients can be made compatible with the psychophysiological limits of the human personality.
...
PMID:[Palliative demolitive surgery]. 4 19

Twenty-two children with rhabdomyosarcoma were treated with combination chemotherapy using vincristine, actinomycin D, and cyclophosphamide for varying time periods. Chemotherapy, usually combined with radiation therapy, was given to early stage patients after they had had a com plete or partial tumor resection. Three of nine patients who had widespread metastatic (stage III) disease at initiation of therapy had complete tumor regression and four of nine had partial tumor regression. However, the median durations of response and survival were brief (3 and 8 months respectively). Five patients with localized resectable (stage I) disease have survived without evidence of tumor recurrence from 33 to 69 months after their initial diagnosis. Of eight patients with incompletely resected regional (stage IIB) disease, one has survived without disease recurrence for 36 months, thought the median survival time of the remaining seven patients was 14 months. In stage IIB patients the duration of response was proportional to the duration of chemotherapy which suggests that chemotherapy should be given for at least 18-24 months.
Cancer Chemother Rep
PMID:Combined chemotherapy in childhood rhabdomyosarcoma. 5 Jan 23

Sera from normal (C57BL/6XC3H/Anf)F1(B6C3F1) mice reacted with several biologically distinct murine leukemia virus(es) (MuLV) by radioimmune precipitation assays with the use of purified tritiated leucine-labeled virus. The reactivities of this natural antibody to viral envelope antigens of two laboratory strains (Rauscher and Moloney) and two endogenous mouse C-type viruses (AKR and BALB:virus-2) were further analyzed and compared by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Similar patterns of antibody reactivities to AKR MuLV and the two member viruses of the Friend-Moloney-Rauscher group were found. Three major antigenic determinants of the virus envelope, gp71, gp43, and p15, were recognized by and precipitated natural antibody. In all viruses examined, normal B6C3F1 sera precipitated comparable amounts of gp71 and gp43. However, compared with the other viruses, the amount of p15 (relative to the glycoproteins) precipitating from BALB:virus-2 was significantly lower. This appears to be due to a lesser amount of p15 on the xenotropic virus. While heterologous antisera to purified gp71 and p15 of MuLV reacted to a certain degree with rhabdomyosarcoma virus 114 and rat leukemia virus, natural mouse antibody did not. These results suggest that MuLV have common antigenic determinants recognized by natural antibody, and that the reactivities of natural antibody in an autogenous immune response are restrictive in contrast to immune antibody produced in a heterologous host.
J Natl Cancer Inst 1975 Oct
PMID:Autogenous immunity to endogenous RNA tumor virus: reactivity of natural immune sera to antigenic determinants of several biologically distinct murine leukemia viruses. 5 18

Cell-free extracts of the human rhabdomyosarcoma cell line HUS-2 caused the transformation of human embryo fibroblasts. This transformation included morphologic alteration, karyotypic change, and an increase in culture longevity. With the use of sex markers, multiple karyotypes confirmed that the human embryo fibroblasts were transformed, and the use of cell-free material further suggested the presence of a transforming virus. RNA-dependent DNA polymerase activity in a particle with a specific gravity of 1.16 g/cm3 indicated the presence of an RNA type C virus. Evidence also suggested that the known mammalian type C viruses, routine cytopathic effect-inducing viruses, or mycoplasma were not the agents responsible for the transformation. That both the donor (HUS-2) and converted (HUE-T) cell lines cross-reacted with antisera prepared against HUE-T indicated a common antigen arising in the process of conversion of HUS-2 cells to HUE-T cells.
J Natl Cancer Inst 1978 May
PMID:Transformation of human embryo cells with the use of cell-free extracts of a human rhabdomyosarcoma cell line (HUS-2): brief communication. 7 83

An RNA-direct DNA polymerase was purified from human melanoma tissue by successive column chromatography on DEAE-cellulose (DE-23 and DE-52) and phosphocellulose. The purified reverse transcriptase has a mol. wt. of 68,000, a pH optimum of 8.0, a Mn2+ optimum of 0.6 mM, and a KCl optimum of 60 mM. The purified enzyme transcribes (rA)n - (dT)12, (rC)n - (dG)18, (Ome-rC)n - (dG)18 and a 70s RNA from Rauscher leukemia virus (RLV), but failed to transcribe (dA)n - (dT)12. This enzyme has no terminal deoxynucleotidyl transferase activity. Serological studies have shown that the reverse transcriptase from human melanoma tissue is antigenically not related to DNA polymerases from Simian sarcoma virus (SiSV), Avian myeloblastosis virus (AMV), RLV, and human spleen of a patient with myelofibrosis. The purified enzyme showed a close antigenic resemblance to DNA polymerases from baboon endogenous virus (BEV) and rhabdomyosarcoma virus (RD-114), the endogenous virus of the cat.
Cancer Lett 1978 Dec
PMID:Biochemical and immunological characterization of a reverse transcriptase from human melanoma tissue. 8 88

The treatment of soft tissue sarcomas in children at the Joint Center for Radiation Therapy, Children's Hospital Medical Center, and the Sidney Farber Cancer Institute from 1970 to 1976 has been reviewed. Twenty-seven patients were diagnosed with rhabdomyosarcoma, and twenty patients were diagnosed with soft tissue sarcomas of other histologies. An aggressive, combined modality therapeutic approach was applied in the treatment of all patients with emphasis placed on conservation of function. Of irradiated patients, local control was achieved in 96% of those with rhabdomyosarcoma and 85% in other sarcomas. Cumulative relapse-free survival (actuarial) at 5 years is projected at 65% for the rhabdomyosarcoma patients and at 63% for the other sarcoma patients. Although there were differences in chemotherapy regimens (vincristine, actinomycin-D and cyclophosphamide for rhabdomyosarcoma and adriamycin and DTIC for other soft tissue sarcomas), the surgical and radiation therapeutic approaches are similar for both groups. The high probability of local control using function-conserving surgery and high dose radiation therapy supports this emerging approach. Improvements in survival will require better control of metastatic disease.
Cancer 1978 Sep
PMID:The role of radiation therapy in the treatment of soft tissue sarcomas of childhood. 10 Feb 8

104 patients with various cancer, excluding malignant lymphoma and leukemia, underwent bone marrow biopsy using a Jamshidi needle, regular type. In 100 patients an adequate pice of bone marrow was obtained. In 24 patients metastases were detected in the bone marrow. Metastases were found in 10 of 38 (26.3%) patients with breast cancer, in 5 of 17 (29.4%) patients with lung cancer, in 5 of 10 (50%) patients with cancer of the prostate, in 1 patient with rhabdomyosarcoma, 1 with chordoma and in 2 of 14 patients who underwent biopsy in search of unknown cancer. 71% of the patients with positive findings in the bone marrow had clinical signs of bone involvement, 80% had positive X-ray film and 78.9% had positive skeletal isotope survey. Hemogram, serum alkaline phosphatase, serum calcium level and sedimentation rate were of no value in predicting whether the marrow was involved or not. No complications were documented following biopsy. The use of the Jamshidi bone marrow biopsy needle for staging and early detection of metastases in a select group cancer patients is suggested.
...
PMID:Bone marrow biopsy in patients with malignant neoplasms other than lymphomas or leukemia. 11 9

The mitogens concanavalin A (Con A) and bacterial lipopolysaccharide (LPS) stimulated normal spleen cells of DBA/2J, CBA/J, and BALB/c mice about equally in the presence of either isologous or homologous serum. This system revealed that sera from mice with five different methylcholanthrene-induced rhabdomyosarcomas inhibited mitogen stimulation of normal spleen cells. Sera from mice with a mammaryadenocarcinoma and spontaneous rhabdomyosarcoma were similarly suppressive. In contrast, sera from mice with melanoma were not inhibitory and often enhanced stimulation. Sera from tumor-bearing animals had the same effects both qualitatively and quantitatively on cells from the strain carrying the tumor and on cells from the other two strains. The mixed lymphocyte response of CBA/J times BALB/c spleen cells was affected exactly as were the responses to mitogen by the various sera. Stimulation by mitogen of mouse lymph-node cells and spleen cells with macrophages removed, as well as that of guinea pig spleen cells, was also inhibited by sera from mice with rhabdomyosarcoma and mammary adenocarcinoma.
J Natl Cancer Inst 1975 Mar
PMID:Effects of sera from tumor-bearing mice on mitogen and allogeneic cell stimulation of normal lymphoid cells. 12 99

Actinomycin D and neoarsphenamine were tested for their ability to produce therapeutically favorable radiosensitization in the WAG/Rij rat. Acute and late skin reactions and control of the BA1112 rhabdomyosarcoma were examined in drug-treated and untreated animals irradiated in single- and five-fraction schedules. Actinomycin D was found to protect skin and tumors when added 15 minutes before irradiation. Actinomycin D added 2 hours before irradiation in a five-fraction trial produced slight tumor sensitization accompanied by slight skin protection. Neoarsphenamine produced significant tumor sensitization without skin sensitization in one of the single-fraction trials, but had no effect in the five-fraction trials.
Cancer Treat Rep 1978 May
PMID:Effect of actinomycin D and neoarsphenamine on tumor control and skin tolerance in the rat. 14 67

Among malignant tumor of the orbit in children, rhabdomyosarcoma remains the most frequent; it should be suspected on any unilateral exophthalmia. Twenty cases have been treated in the "Institut Gustave Roussy" (1960--1975). It can be shown with polychimiotherapy and a better coordination in timing of the other therapies, the survival rate improved clearly. In addition, since 1972 more localized forms have been treated. In the future, the survival rate is supposed to improve yet, if the diagnosis is made earlier. In such conditions a recovery with few inconveniences may be expected. Exenteration is an important mutilation and do not supply a better protection. A secondary inucleation due to complications of radio-therapy is not an exception. However a prothesis will be possible later.
...
PMID:[Actual treatment of rhabdomyosarcoma of the orbit in children (author's transl)]. 15 5


1 2 3 4 5 6 7 8 9 10 Next >>